Citizens Financial Group Inc. RI Raises Stock Position in Novo Nordisk A/S (NYSE:NVO)

Citizens Financial Group Inc. RI lifted its position in Novo Nordisk A/S (NYSE:NVO) by 1.9% in the third quarter, Holdings Channel reports. The firm owned 14,301 shares of the company’s stock after buying an additional 263 shares during the period. Citizens Financial Group Inc. RI’s holdings in Novo Nordisk A/S were worth $1,703,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Natixis Advisors LLC raised its holdings in shares of Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Zions Bancorporation N.A. raised its stake in Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after buying an additional 6,726 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in Novo Nordisk A/S by 14.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after buying an additional 37,346 shares in the last quarter. Private Wealth Partners LLC lifted its holdings in Novo Nordisk A/S by 155.1% during the third quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock worth $3,953,000 after buying an additional 20,188 shares during the period. Finally, Buckingham Capital Management Inc. bought a new stake in Novo Nordisk A/S during the 3rd quarter valued at $3,874,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Performance

NVO opened at $105.07 on Friday. The company has a market cap of $471.50 billion, a P/E ratio of 34.00, a price-to-earnings-growth ratio of 1.32 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm’s 50-day moving average price is $115.48 and its 200-day moving average price is $128.79. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.